Prediction of survival benefits from progression-free survival benefits in advanced non-small-cell lung cancer: evidence from a meta-analysis of 2334 patients from 5 randomised trials | BMJ Open
LENVIMA® (lenvatinib) HCP Website | Overall Survival (OS)
Difference in median overall survival (OS) (months) of individual therapies per International Classification of Diseases 10th revision (ICD–10) category. - ppt download
REVEL Trial Overall Survival for | CYRAMZA® (ramucirumab)
Efficacy of KISQALI® (ribociclib) + AI in Premenopausal | HCP
Extrapolation from Progression-Free Survival to Overall Survival in Oncology
IMFINZI® (durvalumab) Efficacy & Clinical Trials for NSCLC
Optimization of PD-L1 algorithm for predicting overall survival (OS) in patients with urothelial cancer (UC) treated with durvalumab monotherapy
Significant predictors of overall survival in patients with hepatocellular carcinoma after surgical resection | PLOS ONE
Historical time to disease progression and progression-free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early-phase trials. - Abstract - Europe PMC
Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study - ScienceDirect
Exploring the relationship between Overall Survival (OS), Progression Free Survival (PFS) and Objective Response Rate (ORR) in patients with advanced melanoma - ScienceDirect
Progression-free survival as a surrogate for overall survival in oncology trials: a methodological systematic review | British Journal of Cancer
Surrogate endpoints for overall survival in advanced non‑small‑cell lung cancer patients with mutations of the epidermal growth factor receptor gene
Real-world treatment patterns and survival outcomes for advanced non-small cell lung cancer in the pre-immunotherapy era in Portugal: a retrospective analysis from the I-O Optimise initiative | BMC Pulmonary Medicine | Full
Final overall survival (OS) data from FLAURA trial - YouTube
PSE investigates the correlation between OS and PFS at ESMO 2017
A nomogram-based immunoprofile predicts overall survival for previously untreated patients with esophageal squamous cell carcinoma after esophagectomy | Journal for ImmunoTherapy of Cancer | Full Text
Overall survival (OS) by circulating tumor DNA (ctDNA) status in patients with post-operative muscle-invasive urothelial carcinoma (MIUC) treated with atezolizumab (atezo): update from IMvigor010 - UROONCO Bladder Cancer
Figure 1. Overall survival (OS) curve according to performance status(PS) of the study cohort of patients with advanced non-small cell lung cancer (mean OS of PS 0= 18.41, PS 1= 10.76, PS
A correlation analysis to assess event-free survival as a trial-level surrogate for overall survival in early breast cancer - eClinicalMedicine
Characterizing the Feasibility and Performance of Real-World Tumor Progression End Points and Their Association With Overall Survival in a Large Advanced Non–Small-Cell Lung Cancer Data Set | JCO Clinical Cancer Informatics
View Image
![PDF] Review of meta-analyses evaluating surrogate endpoints for overall survival in oncology | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/eb56a0ed555af54134d5949c8b856bff15592fe4/3-Figure1-1.png "PDF] Review of meta-analyses evaluating surrogate endpoints for overall survival in oncology | Semantic Scholar")
PDF] Review of meta-analyses evaluating surrogate endpoints for overall survival in oncology | Semantic Scholar
VENCLEXTA® (venetoclax tablets) | VIALE-A Trial Overall Survival Data
